What is the typical starting dose and administration schedule for NPH (Neutral Protamine Hagedorn) insulin?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

NPH Insulin: Starting Dose and Administration Schedule

For type 2 diabetes, initiate NPH insulin at 10 units per day or 0.1-0.2 units/kg/day (approximately 7-14 units for a 70 kg patient), administered once daily at bedtime, in conjunction with metformin. 1

Standard Dosing for Type 2 Diabetes

Basal insulin initiation:

  • Start with 10 units per day as a fixed dose, OR 1
  • Calculate 0.1-0.2 units/kg/day based on body weight and degree of hyperglycemia 1
  • Administer as a single bedtime injection when used as basal insulin 1

Titration strategy:

  • Equip patients with a self-titration algorithm based on self-monitoring of blood glucose 1
  • Adjust doses frequently based on fasting glucose targets 1

Alternative Dosing Schedules

Twice-daily NPH regimen:

  • When combined with regular insulin in a 70/30 premixed formulation, administer before breakfast and before dinner 1
  • This provides both basal and prandial coverage with each injection 1

Three-times-daily NPH:

  • For patients on continuous enteral/parenteral nutrition, administer NPH every 8 or 12 hours to cover nutritional requirements 1
  • Calculate as 1 unit of insulin for every 10-15 grams of carbohydrate in the feeding formula 1

Special Clinical Contexts

Steroid-induced hyperglycemia:

  • Administer NPH in the morning (not bedtime) to match the peak hyperglycemic effect of glucocorticoids 2, 3
  • Start with 0.1-0.2 units/kg/day as the initial dose 2
  • NPH peaks at 4-6 hours, which aligns with steroid-induced hyperglycemia timing 1, 2
  • For high-dose glucocorticoids, expect to increase doses by 40-60% or more above standard requirements 1, 3

Hospitalized patients:

  • Continue basal insulin in patients with type 1 diabetes even if NPO to prevent diabetic ketoacidosis 1
  • Add correctional insulin subcutaneously every 6 hours with regular human insulin 1
  • If enteral nutrition is interrupted, start dextrose infusion immediately to prevent hypoglycemia 1, 4

Important Clinical Considerations

Advantages of NPH:

  • Less expensive than long-acting basal analogs (glargine, detemir) 1
  • Effective when administered twice daily for patients requiring more intensive coverage 5

Disadvantages compared to long-acting analogs:

  • Peak insulin activity occurs 4-6 hours after administration, increasing nocturnal hypoglycemia risk 6
  • More variable pharmacokinetic profile compared to glargine or detemir 7
  • When used as basal insulin, long-acting analogs (U-100 glargine or detemir) can be used instead of NPH for more predictable glucose control 1

Common Pitfalls to Avoid

  • Do not use NPH alone for steroid-induced hyperglycemia at bedtime - morning administration is essential to match steroid timing 2, 3
  • Do not forget basal insulin in type 1 diabetes patients who are NPO or have feeding interruptions 1
  • Avoid relying solely on correctional insulin without adequate basal coverage, as this leads to poor glycemic control 1
  • Monitor closely for hypoglycemia when NPH is given at bedtime due to peak action during sleep hours 6
  • Coordinate meal delivery with insulin administration in hospitalized patients to prevent hypo- and hyperglycemic events 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of Steroid-Induced Hyperglycemia with NPH Insulin

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

NPH Insulin Regimen for Steroid-Induced Hyperglycemia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Adjusting NPH Insulin for Increased Tube Feeding Rate

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Insulin glargine versus NPH insulin in patients with type 1 diabetes.

Drugs of today (Barcelona, Spain : 1998), 2003

Related Questions

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.